--- title: "更新：Regenxbio 股价在第一季度由盈转亏后下跌，收入减少；RGX-202 的第三阶段研究达到了主要终点" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/286455339.md" description: "Regenxbio 的股价在报告第一季度每股摊薄净亏损 1.72 美元后下跌了 36%，而去年同期的收益为每股 0.12 美元。收入从 8900 万美元降至 640 万美元，未能达到分析师的预期。该公司拥有 1.505 亿美元的现金，可以支持其运营到 2027 年初。然而，其基因疗法 RGX-202 在第三阶段试验中达到了主要终点，计划申请加速批准，并有望在 2027 年进行商业发布" datetime: "2026-05-14T18:39:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286455339.md) - [en](https://longbridge.com/en/news/286455339.md) - [zh-HK](https://longbridge.com/zh-HK/news/286455339.md) --- # 更新：Regenxbio 股价在第一季度由盈转亏后下跌，收入减少；RGX-202 的第三阶段研究达到了主要终点 02:39 PM EDT, 05/14/2026 (MT Newswires) -- (Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.) Regenxbio's ( RGNX ) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined. The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier. Analysts polled by FactSet expected a loss of $1.34. Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier. Analysts surveyed by FactSet expected $25.8 million. The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027. Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy. The company said 93% of patients achieved over 10% microdystrophin expression at week 12. Regenxbio ( RGNX ) said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027. Price: 6.47, Change: -3.57, Percent Change: -35.56 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited. ### 相关股票 - [RGNX.US](https://longbridge.com/zh-CN/quote/RGNX.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [FDS.US](https://longbridge.com/zh-CN/quote/FDS.US.md) ## 相关资讯与研究 - [Regenxbio｜10-Q：2026 财年 Q1 营收 6.39 百万美元不及预期](https://longbridge.com/zh-CN/news/286408635.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [XORTX 获战略投资](https://longbridge.com/zh-CN/news/286767527.md) - [Regenxbio 宣布 RGX-202 关键性 III 期 AFFINITY DUCHENNE®研究的积极顶线结果 | RGNX 股票新闻](https://longbridge.com/zh-CN/news/286403513.md) - [渤健二期临床试验未达主要终点，多家律所发起证券欺诈调查](https://longbridge.com/zh-CN/news/286796113.md)